Patent ID: 8586577

Claim:
A method for selectively inhibiting 11β-HSD1 enzyme in a patient; or for treating a disease caused, mediated and/or propagated by high cortisol levels; or for treating a disease or condition selected from the group consisting of metabolic syndrome, diabetes type II, non-insulin dependent diabetes mellitus, prediabetes, insulin resistance, low glucose tolerance, hyperglycemia, obesity, weight-related disorders, lipid disorders, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, glaucoma, osteoporosis, glucocorticoid-mediated effects on neuronal function, cognitive impairment, anxiety, depression, neurodegenerative disease, immune disorders, tuberculosis, leprosy, psoriasis, hypertension, atherosclerosis, sequelae or atherosclerosis, vascular restenosis, cardiovascular diseases, pancreatitis, retinopathy, neuropathy and nephropathy, comprising administering to the patient an effective amount of a compound of formula I wherein R 1 , R 2 are, independently from each other, alkyl or cycloalkyl, wherein the cycloalkyl is optionally substituted by alkyl or hydroxyl, or R 1 , R 2 and the nitrogen to which they are attached form a saturated mono or bicyclic ring containing 6-10 atoms, optionally containing one further N, S or O atom and optionally substituted by a Hal, alkyl, hydroxyl, ═O (carbonyl oxygen) or aryl, or heteroaryl, R 3 is alkyl, cycloalkyl, phenyl or heteroaryl, wherein the phenyl or heteroaryl is optionally substituted by a Hal, alkyl, C 1 -C 4 -alkyloxy, trifluoromethyl, trifluoromethoxy, C 1 -C 4 -alkyloxycarbonyl, C 1 -C 4 -alkylcarbonyl or R 4 R 5 NC 1 -C 4 -alkyloxy, and R 4 , R 5 are, independently from each other, C 1 -C 4 alkyl or C 4 -C 8 -cycloalkyl, or a pharmaceutically acceptable salt thereof or a derivative thereof.